coin-img-ETHETH-5.50%coin-img-BTCBTC-3.98%coin-img-SOLSOL-4.46%coin-img-ROBOROBO-8.23%coin-img-AITOAITO-55.07%coin-img-CRKCRK+237.73%coin-img-XRPXRP-3.54%coin-img-USDCUSDC+0.01%coin-img-ETHETH-5.50%coin-img-BTCBTC-3.98%coin-img-SOLSOL-4.46%coin-img-ROBOROBO-8.23%coin-img-AITOAITO-55.07%coin-img-CRKCRK+237.73%coin-img-XRPXRP-3.54%coin-img-USDCUSDC+0.01%coin-img-ETHETH-5.50%coin-img-BTCBTC-3.98%coin-img-SOLSOL-4.46%coin-img-ROBOROBO-8.23%coin-img-AITOAITO-55.07%coin-img-CRKCRK+237.73%coin-img-XRPXRP-3.54%coin-img-USDCUSDC+0.01%coin-img-ETHETH-5.50%coin-img-BTCBTC-3.98%coin-img-SOLSOL-4.46%coin-img-ROBOROBO-8.23%coin-img-AITOAITO-55.07%coin-img-CRKCRK+237.73%coin-img-XRPXRP-3.54%coin-img-USDCUSDC+0.01%
user-avatar
Tim Fries

ImmunityBio Stock Rises After NCCN Adds ANKTIVA Plus BCG for Papillary NMIBC in 2026 Bladder Cancer Guidelines

On March 17, 2026, ImmunityBio shares climbed in premarket trading after ANKTIVA in combination with BCG was added to the NCCN's 2026 bladder cancer guidelines with a Category 2A recommendation for BCG-unresponsive papillary-only NMIBC. The move followed strong year-to-date stock gains, detailed clinical data from the QUILT-3.032 study, and comes as the company awaits FDA review for this additional indication.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.